Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) is pleased to invite analysts, investors and media to its Virtual Capital Markets Day on 10 December 2020 at 13:00-16:00 CET.
Presentations will be given by CEO Guido Oelkers, Head of R&D and Chief Medical Officer Ravi Rao, Head of Immunology & International Norbert Oppitz, and CFO Henrik Stenqvist.
Agenda in brief:
The event will start at 13:00 and will be broadcast live.
The live webcast can be followed on: Sobi Capital Markets Day 2020
A Q&A session will follow the presentations.
Dial-in details for the conference call are:
Sweden (Sverige): +46 8 505 583 74
United Kingdom: +44 333 300 9272
United States: +1 844 625 1570
Please visit sobi.com for more information.
Recordings of the presentations, and the presentations themselves, will be made available on the website, in the Investors section.
About Sobi
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,500 people across Europe, North America, the Middle East, Russia and North Africa. In 2019, Sobi's revenue amounted to SEK 14.2 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at www.sobi.com.
Contact
Paula Treutiger, Head of Communication & Investor Relations
+ 46 733 666 599
[email protected]
Swedish Orphan Biovitrum AB (publ)
Postal address SE-112 76 Stockholm, Sweden
Phone: 46 8 697 20 00 www.sobi.com
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Find out more about our business and financial performance.
Here we present our most recent press releases, news articles, and images.
Every day, we work actively to find better ways to understand and meet patient needs.